Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
03 avr. 2024 06h30 HE
|
Aanastra Inc
Aanastra to present its RNA peptide therapeutics technology at AACR conference
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
28 mars 2024 11h03 HE
|
Knight Therapeutics
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on...
MetasTx LLC Celebrates Dr. David Crich’s Achievement of the 2024 James Flack Norris Award in Physical Organic Chemistry
25 mars 2024 07h48 HE
|
MetasTx LLC
Dr. David Crich, Georgia Research Alliance, and David Chu, Eminent Scholar In Drug Design and Head of Chemistry at MetasTx honored.
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
21 mars 2024 07h58 HE
|
CAMP4 Therapeutics
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
21 mars 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
14 mars 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
14 mars 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and...
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
14 mars 2024 05h00 HE
|
S. M. Discovery Group (SMDG)
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
29 févr. 2024 09h54 HE
|
PRISM MarketView
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
29 févr. 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi®...